Clinical Trial Update: A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of BI 1387446 alone or in combination with Ezabenlimab (BI 754091) in patients with advanced or metastatic solid tumors has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BI 1387446
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-06-12